Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 2 » Issue 3

Factors affecting health status in COPD patients with co-morbid anxiety or depression

Authors Minna J Hynninen, Ståle Pallesen, Inger Hilde Nordhus

Published 15 October 2007 Volume 2007:2(3) Pages 323—328

Minna J Hynninen¹, Ståle Pallesen², Inger Hilde Nordhus¹

¹Department of Clinical Psychology, University of Bergen, Norway ²Department of Psychosocial Science, University of Bergen, Norway

Abstract: Health status questionnaires provide standardized measures of patients’ perceptions of the impact of disease on their daily life and well-being. Factors associated with health status were examined in a sample of 58 outpatients with chronic obstructive pulmonary disease (COPD) and co-morbid anxiety and/or depression. A cross-sectional descriptive study was conducted with the following measures: The St. George’s Respiratory Questionnaire (SGRQ); the Beck Anxiety Inventory (BAI); the Beck Depression Inventory, 2nd edition (BDI); the Pittsburgh Sleep Quality Index (PSQI); and spirometry. Disease severity as measured with spirometry was not related to health status. Perceptions of poor health as implied by the health status scores were positively associated with symptoms of anxiety and depression, sleep disturbances, and level of daily functioning. There were statistically significant differences between men and women on COPD severity, age, and the BAI scores. The findings emphasize the importance of screening the patients at all stages of disease severity for anxiety, depression, and sleeping problems, in order to provide adequate care for these problems.

Keywords: COPD, health status, health-related quality of life, anxiety, depression, sleep

Download Article [PDF] 

Readers of this article also read:

Lefty-1 alleviates TGF-β1-induced fibroblast–myofibroblast transdifferentiation in NRK-49F cells

Zhang LJ, Zhang J, Xu CG, Zhou XJ, Wang W, Zheng RP, Hu W, Wu P

Drug Design, Development and Therapy 2015, 9:4669-4678

Published Date: 14 August 2015

Evaluating inhaler use technique in COPD patients

Pothirat C, Chaiwong W, Phetsuk N, Pisalthanapuna S, Chetsadaphan N, Choomuang W

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1291-1298

Published Date: 8 July 2015

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles

Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS

Drug Design, Development and Therapy 2015, 9:2609-2616

Published Date: 13 May 2015

Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature

Cui QY, Shen HS, Wu TQ, Chen HF, Yu ZQ, Wang ZY

Drug Design, Development and Therapy 2015, 9:2395-2398

Published Date: 24 April 2015

Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study

Abourehab MA, Khaled KA, Sarhan HA, Ahmed OA

Drug Design, Development and Therapy 2015, 9:2159-2169

Published Date: 13 April 2015

Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Liang SY, Zhou Q, Wang M, Zhu YH, Wu QZ, Yang XL

International Journal of Nanomedicine 2015, 10:2325-2333

Published Date: 23 March 2015

Pathophysiology of viral-induced exacerbations of COPD

Potena Alfredo, Caramori Gaetano, Casolari Paolo, Contoli Marco, Sebastian L Johnston, et al

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:477-483

Published Date: 15 January 2008